The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience

Sim V.; Forner S.; Burcombe R.; Glendenning J.

首页> 外文期刊>Clinical oncology >The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience

【24h】

The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience

机译：将Pertuzumab添加到Neoadjuvant Her2针对病理完全反应（PCR）的影响：肯特肿瘤学中心（Koc）体验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical oncology》 |2019年第7期|共1页
作者
Sim V.; Forner S.; Burcombe R.; Glendenning J.;
展开▼
作者单位

Kent Oncol Ctr Maidstone Kent England;

Kent Oncol Ctr Maidstone Kent England;

Kent Oncol Ctr Maidstone Kent England;

Kent Oncol Ctr Maidstone Kent England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience [J] . Sim V., Forner S., Burcombe R., Clinical oncology . 2019,第7期

机译：将Pertuzumab添加到Neoadjuvant Her2针对病理完全反应（PCR）的影响：肯特肿瘤学中心（Koc）体验
2. The differential impact of non-anthracycline treatment regimens on pathological complete response (pCR) rates by ER status after neoadjuvant single or dual HER2 targeted therapy (NACT): A single centre experience [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：非蒽环治疗方案对Neoadjuvant单身或双HER2靶向治疗（NACT）后ER状态对病理完全反应（PCR）率的差异影响（PCR）：单一中心经验
3. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies [J] . Sinead Toomey, Alexander J. Eustace, Joanna Fay, Breast Cancer Research . 2017,第1期

机译：体细胞PI3K途径和ERBB家族突变对接受新辅助HER2靶向治疗的HER2阳性乳腺癌患者的病理完全缓解（pCR）的影响
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies [O] . Sinead Toomey, Alexander J. Eustace, Joanna Fay, 2017

机译：体细胞PI3K途径和ERBB家族突变对接受新辅助HER2靶向治疗的HER2阳性乳腺癌患者的病理完全缓解（pCR）的影响
7. Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience [O] . Katalin Boér, Zsuzsanna Kahán, László Landherr, 2021

机译：在早期Her2阳性乳腺癌中，Neoadjuvant Pertuzumab和Trastuzumab与化疗后的病理完整反应率和胸瘤癌的乳腺保护外科率增加：真实世界经验
8. Guidance for Industry Pathological Complete Response in Neo-Adjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. [R] . 2014

机译：新辅助治疗高风险早期乳腺癌的工业病理完全反应指南：用作支持加速批准的终点。

The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience

著录项

相似文献

相关主题

期刊订阅